Paul Hastings Advises Ligand Pharmaceuticals on Its $700 Million Convertible Senior Notes Offering
June 26, 2026
June 26, 2026
LOS ANGELES, California, June 26 [Category: BizLaw/Legal] -- Paul Hastings, a law firm, issued the following news:
* * *
Paul Hastings Advises Ligand Pharmaceuticals on Its $700 Million Convertible Senior Notes Offering
*
Paul Hastings LLP advised Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines, in connection with . . .
* * *
Paul Hastings Advises Ligand Pharmaceuticals on Its $700 Million Convertible Senior Notes Offering
*
Paul Hastings LLP advised Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines, in connection with . . .